The EU's pharma reform makes market protection more conditional. Here is how US drugmakers, especially startups, can adapt and use IP to complement it.
Daniel Goodman
Advertisement
Daniel Goodman is a partner at Carpmaels & Ransford LLP.
Articles by Daniel Goodman
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How Rebate Timing Distorts a Pharmacy's 340B Books
2
EU Pharma Reform: Strategic Implications for US Drugmakers
3
White House Extends MFN Pricing to Every State Medicaid Program
4
Pharma Pulse: Behind the Scenes of LogiPharma USA 2026
5